全文获取类型
收费全文 | 22721篇 |
免费 | 1315篇 |
国内免费 | 164篇 |
专业分类
耳鼻咽喉 | 321篇 |
儿科学 | 421篇 |
妇产科学 | 539篇 |
基础医学 | 2689篇 |
口腔科学 | 745篇 |
临床医学 | 1805篇 |
内科学 | 6134篇 |
皮肤病学 | 406篇 |
神经病学 | 2255篇 |
特种医学 | 731篇 |
外科学 | 3425篇 |
综合类 | 82篇 |
一般理论 | 9篇 |
预防医学 | 1042篇 |
眼科学 | 306篇 |
药学 | 1517篇 |
1篇 | |
中国医学 | 42篇 |
肿瘤学 | 1730篇 |
出版年
2023年 | 141篇 |
2022年 | 142篇 |
2021年 | 584篇 |
2020年 | 384篇 |
2019年 | 552篇 |
2018年 | 637篇 |
2017年 | 474篇 |
2016年 | 562篇 |
2015年 | 603篇 |
2014年 | 916篇 |
2013年 | 1167篇 |
2012年 | 1801篇 |
2011年 | 1787篇 |
2010年 | 1061篇 |
2009年 | 942篇 |
2008年 | 1627篇 |
2007年 | 1556篇 |
2006年 | 1470篇 |
2005年 | 1477篇 |
2004年 | 1371篇 |
2003年 | 1249篇 |
2002年 | 1147篇 |
2001年 | 156篇 |
2000年 | 150篇 |
1999年 | 158篇 |
1998年 | 154篇 |
1997年 | 149篇 |
1996年 | 142篇 |
1995年 | 159篇 |
1994年 | 130篇 |
1993年 | 122篇 |
1992年 | 105篇 |
1991年 | 63篇 |
1990年 | 82篇 |
1989年 | 68篇 |
1988年 | 74篇 |
1987年 | 75篇 |
1986年 | 58篇 |
1985年 | 61篇 |
1984年 | 73篇 |
1983年 | 70篇 |
1982年 | 67篇 |
1981年 | 57篇 |
1980年 | 53篇 |
1979年 | 29篇 |
1978年 | 35篇 |
1977年 | 25篇 |
1976年 | 20篇 |
1975年 | 16篇 |
1971年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
31.
32.
33.
34.
35.
Giuseppe Rollo Gabriele Falzarano Mario Ronga Michele Bisaccia Predrag Grubor Rocco Erasmo Guido Rocca Felix Tomé-Bermejo David Gómez-Garrido Paolo Pichierri Giuseppe Rinonapoli Luigi Meccariello 《Injury》2019,50(2):453-461
Introduction
Floating knee is a flail knee joint resulting from fractures of the shafts or adjacent metaphyses of the femur and the ipsilateral tibia. It is usually associated with several complications and mortality. This study was designed to present our experience with the treatment of this injury.Material and method
This study was performed between January 2004 and December 2014. 224 cases of floating knee injuries gathered from the 34,480 lower extremities trauma files were studied, and the target information recorded. The injuries most frequently occurred in subjects between 16 and 35 years of age (60.71%), and in male subjects (85.71%). The most frequent mechanism of injury was traffic accident (92.85%). External fixation was the common type of treatment (82.14%) in emergency or as a definitive treatment. The treatment was performed within 24?h of the trauma. We performed a 36-month follow up with clinical examination, radiographs, assessing the complications, and using the Modified Cincinnati Rating System Questionnaire (MCRSQ) and the Karlström/Olerud Score (KOS) to evaluate the progression of the outcomes.Results
Early complications included 8 cases of compartment syndrome, 60 open fractures and 24 partially amputated limbs. A total amputation was performed in 3 patients. The most common late complication was heterotopic calcifications of the knee (n?=?68, 30.6%). Good scores for MCRSQ and KOS were obtained only after patients were sent to a reference center for knee surgery.Conclusions
Our experience revealed that the complication rate associated with floatingknee injuries remains high, regardless of the performed treatment. Surgeons should focus on reducing complications while treating these severe injuries. 相似文献36.
Matteo Lambertini Francesca Poggio Marco Bruzzone Benedetta Conte Claudia Bighin Evandro de Azambuja Mario Giuliano Michele De Laurentiis Francesco Cognetti Alessandra Fabi Giancarlo Bisagni Antonio Durando Anna Turletti Ylenia Urracci Ornella Garrone Fabio Puglisi Filippo Montemurro Marcello Ceppi Lucia Del Mastro the GIM investigators 《International journal of cancer. Journal international du cancer》2020,147(1):160-169
Dose-dense adjuvant chemotherapy is standard of care in high-risk early breast cancer patients. However, its role in HER2-positive patients is still uncertain. In this exploratory analysis of the GIM2 trial, we investigated the efficacy of dose-dense chemotherapy in HER2-positive breast cancer patients with or without exposure to trastuzumab. In the GIM2 trial, node-positive early breast cancer patients were randomized to receive four cycles of (fluorouracil)epirubicin/cyclophosphamide followed by four cycles of paclitaxel administered every 2 (dose-dense) or 3 (standard-interval) weeks. After approval of adjuvant trastuzumab, protocol was amended in April 2006 to allow use of trastuzumab for 1 year after chemotherapy completion in HER2-positive patients. The efficacy of dose-dense chemotherapy in terms of disease-free survival (DFS) and overall survival (OS) was assessed according to HER2 status and trastuzumab use. Out of 2,003 breast cancer patients, HER2 status was negative/unknown in 1,551 patients; among the 452 patients with HER2-positive breast cancer, chemotherapy alone or followed by trastuzumab was given to 320 and 132 patients, respectively. Median follow-up was 8.1 years. No significant interaction between HER2 status, trastuzumab use and chemotherapy treatment was observed for both DFS (p = 0.698) and OS (p = 0.708). Nevertheless, there was no apparent benefit in the HER2-positive group treated with trastuzumab (DFS: HR, 0.99; 95% CI 0.52–1.89; OS: HR, 0.95; 95% CI 0.37–2.41). Although dose-dense chemotherapy was associated with a significant survival improvement in high-risk breast cancer patients, its benefit appeared to be smaller (if any) in patients with HER2-positive disease who received adjuvant trastuzumab. 相似文献
37.
38.
39.
40.
Cost‐Effectiveness and Cost‐Utility Analysis of Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome: Results From the PRECISE Study 下载免费PDF全文
Furio Zucco MD Roberta Ciampichini MSc Angelo Lavano MD Amedeo Costantini MD Marisa De Rose MD Paolo Poli MD Gianpaolo Fortini MD Laura Demartini MD Enrico De Simone MD Valentino Menardo MD Piero Cisotto MD Mario Meglio MD Luciana Scalone PhD Lorenzo G. Mantovani DSc 《Neuromodulation》2015,18(4):266-276